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Abstract
One of the approaches by which the scientific community is seeking to cure HIV is the use of
therapeutic vaccination. Previous studies have highlighted the importance of the virus-spe-
cific CD8+ T cell cytotoxic responses for the immune control of HIV and have oriented
research on vaccine constructs based on CTL epitopes from circulating HIV-1 strains. The
clinical trials with therapeutic vaccines to date have had limited success likely due to (i) a dis-
crepancy between archived CTL epitopes in the viral reservoir and those in circulating vi-
ruses before antiretroviral therapy (ART) initiation and (ii) the lack of strong affinity between
the selected CTL epitopes and the HLA grooves for presentation to CD8+ cells. To over-
come these limitations, we launched the Provir/Latitude 45 study to identify conserved CTL
epitopes in archived HIV-1 DNA according to the HLA class I alleles of aviremic patients,
most of whom are under ART. The near full-length genomes or Gag, Pol and Nef regions of
proviral DNA were sequenced by Sanger and/or Next Generation Sequencing (NGS). The
HLA-A and B alleles were defined by NGS or molecular analysis. The TuTuGenetics soft-
ware, which moves a sliding window of 8 to 10 amino acids through the amino acid align-
ment, was combined with the Immune Epitope Data Base (IEDB) to automatically calculate
the theoretical binding affinity of identified epitopes to the HLA alleles for each individual.
We identified 15 conserved epitopes in Pol (11), Gag (3), and Nef (1) according to their
potential presentation by the dominant HLA-A and B alleles and now propose to use the cor-
responding conserved peptides in a multi-epitopic vaccine (HLA-fitted VAC, HFVAC).
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Introduction
HIV-1 infection is a chronic infection that induces a steady decrease in CD4+ T lymphocytes
and leads to acquired immunodeficiency syndrome (AIDS). The availability of combination
antiretroviral therapies (cART) has made it possible to control viral replication in treated
patients, resulting in at least partial reconstitution of their immune defenses and allowing
them to lead a largely normal life. However, these treatments are costly and have side effects.
Trials in which treatment was discontinued were followed by a rebound of viral replication
[1]. Indeed, after the primary infection phase, HIV-1 establishes a cell reservoir, the CD4
+ memory T cells, where it becomes latent [2] and hides in anatomical reservoirs such as the
central nervous and genital systems plus the lymph nodes, which are not fully permeable to
some antiretroviral molecules, as well as the gastrointestinal associated lymphoid tissues
(GALT). Therefore, viral replication rebounds rapidly in the vast majority of individuals
undergoing a cART interruption.
The scientific and medical communities are now seeking to cure HIV. Several pathways
have been or are being explored [3,4], one of them being therapeutic vaccination. The strategy
is based on vaccinating patients while on effective cART and undetectable viral load. Often,
cART is initiated at the stage of chronic infection, at a moment when the virus has achieved an
antigenic drift, particularly at CTL epitopes, with a resulting escape from immune control [5].
During cART, it seems that viral diversity decreases, that the majority of proviral DNA
genomes are defective (although some viral proteins may be translated, including Gag) and
that the corresponding infected cells are gradually eliminated. Proviral DNA molecules includ-
ing fully infectious genomes are maintained in CD4+ memory T cells following clonal cellular
expansion [6–10]. Viro-immunological studies on primary infection as well as on long-term
non-progressing patients, called elite controllers, have demonstrated the importance of the
CD8+ T cell cytotoxic responses [11] and have mainly oriented research on vaccine constructs
towards this type of response[12,13]. However, the results of the corresponding clinical trials
involving HIV-infected patients on cART are clearly not commensurate with the hope placed
in them [14].
Some comments can be made at this point: (i) most of the vaccine constructs, whether they
are based on recombinant viruses, plasmid DNA or lipopeptides, are designed on generic
HIV-1 viruses and circulating strains may exhibit variations (depending on subtypes or not)
especially regarding the CTL epitopes (ii) the virus resuming after discontinuation of cART
originates from the archived proviral DNA and our team [15,16] plus R. Siliciano ‘s group [17]
have drawn attention to the discrepancy between archived CTL epitopes and CTL epitopes of
the circulating viruses before initiation of cART; (iii) there exist extensive experimental data
that underscore the importance of a high binding affinity of CTL epitopes to their restricting
HLA class I molecule and the recognizing T cell receptor (TCR) [18,19].
We previously raised the hypothesis of a vaccine strategy where the CTL epitopes of the
archived HIV DNA plus the HLA alleles of every patient would be identified, followed by theo-
retical matching of the epitopes for their affinity to the HLA grooves before the synthesis of
“patient-specific lipopeptides”. However, this strategy may pose significant hurdles from an
industrial point of view as personalized vaccines would require individual immunogen
sequences to be synthetized.
We therefore decided to conduct a large study (“Provir/Latitude 45”) in order to identify
conserved HIV proviral CTL epitopes presented by the most prevalent HLA class I alleles in
cART-treated patients of Bordeaux, Rio de Janeiro, Montreal, Lima and Baltimore, plus elite
controllers in the Institute of Human Virology cohort, Baltimore with the objective to design a
more universally usable immunogen sequence. The study focused on the genomic parts of
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HIV-1 which are considered as crucial for CTL epitopes, namely Gag, Pol as well as Nef where
some potentially beneficial epitopes have been described [20].
Results
Main characteristics of population investigated
With the exception of eight elite controllers in Baltimore, all patients (total = 194) have been
on successful cART for at least 6 months. The patients in Montreal were close to primary infec-
tion and their biological follow up has been previously presented [16]: the DNA sequencing
was carried out at a median of 7.5 months post primary infection (range 3–16 months). The
remaining patients were treated and recruited in Provir/Latitude 45 at the chronic stage. This
was the case in Rio de Janeiro, Lima, Baltimore and Bordeaux where 140 patients have been
included. In the Bordeaux cohort, the median duration of cART was 6 years [range 9 months-
21 years], the median number of CD4+ T lymphocytes was 620/μL [range 74–1741] and the
median quantity of proviral DNA was 253 copies/106 PBMC [range <70–3854]. A summary
of the patients’ main characteristics together with the technical strategy used in the study is
presented at the end of “Materials and Methods”.
Main HLA alleles I of investigated population
The most frequent HLA A and B alleles in the population studied are noted in Table 1 and
were selected for simulation of the CTL epitope affinity. The corresponding alleles are:
HLA-A�02:01,�24:02, A�03:01, A�01:01, A�11:01, A�23:01, A�68:02 (please refer to comment
below) and HLA-B�07:02, B�08:01, B�44:03, B�51:01, B�44:02, B�35:01, B�53:01, B�35:01,
B58:01, B�15:01. They were dominant alleles in the Caucasian population except for HLA�
68:02, which is frequently detected in the African population and was observed significantly in
the Bordeaux cohort (7.8% while reference percentages are 6.51 and 0.85 respectively in the
African and Caucasian populations) and which, for this reason, was included in the present
analysis.
HIV-1 subtypes
The HIV-1 B subtype was globally predominant but with some local differences: while B was
the only subtype noted in Baltimore, Lima and Montreal, other viruses were observed in Rio
de Janeiro (F, BF, BC) and in Bordeaux, where the pattern was more complex (CRF02_AG,
CRF11_cpx, CRF01_AE, F, D, C, BF, URF and the new described CRF98_cpx). In Bordeaux,
CRF02_AG accounted for more than 10% of the samples tested.
Table 1. Decreasing frequencies of the HLA alleles A and B of the Provir/Latitude 45 population studied.
HLA-A�02:01 35.1% HLA-B�07:02 18.0%
HLA-A�24:02 17.1% HLA-B�08:01 14.1%
HLA-A�03:01 16.6% HLA-B�44:03 11.7%
HLA-A�01:01 15.1% HLA-B�51:01 10.7%
HLA-A�11:01 7.8% HLA-B�44:02 9.3%
HLA-A�23:01 7.8% HLA-B�35:01 7.3%
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Conserved epitopes
From all the data obtained, we designated 15 conserved epitopes; 11 in RT, three in Gag and
one in Nef according to their potential presentation by the A�02:01 (5 epitopes), A�24:02 (one
epitope), A�03:01 (2 epitopes), A�11:01 (2 epitopes), A�68:02 (one epitope) and HLA-B�07:02
(2 epitopes), B�08:01 (one epitope), B�35:01 (2 epitopes), B�15:01 alleles (one epitope)
(Table 2). The data for the other HLA alleles were not recorded at this step since the IC50 val-
ues for the affinity between epitopes and HLA alleles were above the threshold of 50 nm for
MHC IC50. The 15 epitopes have a length ranging from 8 to 10 residues, most of them (9 out
of 15) being composed of 9 residues. Pol02 (FLWMGYEL) is not described in the Los Alamos
database; Pol03 (YELHPDKWTV), Pol06 (TVQPIVLPEK) and Pol07 (DVGDAYFSV) are
largely overlapping with described epitopes with a shift of one or two residues compared to
epitopes noted in the HIV database; Pol07 (DVGDAYFSV) has a theoretical affinity for
A�68:02 (MHC IC50: 20.2 nM) while it is listed in the database as having affinity for A
�02:01;
Pol10 (SMTKILEPF) was found to have an affinity for the HLA allele B�15:01 (MHC IC50: 24.8
nM) in our in silico study, while no HLA allele is mentioned in the database. The other epi-
topes are already referred to in the database along with a specific HLA class I restriction and
published in vitro functional immunological data.
To be sure that the variability at sequence areas of interest (i.e. coding for conserved CTL
epitopes according to the HLA groove) was not frequently associated per patient with variants
exhibiting an MHC IC50 > 50 nm, we analyzed these areas directly using the NGS Illumina
sequences from Rio de Janeiro, while, in Bordeaux, we analysed first the Sanger data followed
by further investigation using NGS (PGM) Fig 1 shows that the variability at these epitopic
areas is rarely associated with escape mutants. Most of the patients exhibit the epitopes shown
in Table 2 with an MHC IC50 < 50 nm and some variants close to this threshold (e.g. Gag 01).
In some rare cases, there were some variant epitopes (e.g. Gag 02) with a predicted IC50 > 500
nm but with a low percentage (around 1%) in the subspecies per individual. Globally, the
Table 2. List of epitopes identified in the study. For each epitope, its position (gene and position according to the HxB2 reference), the aminoacid sequence, the HLA
allele(s) predicted to have a high affinity to the epitope and the eventual presence in the epitope of drug resistance-associated mutation(s): DRM(s) according to IAS–USA
DRM list (https://www.iasusa.org).
Epitope ID Position (relative to HxB2) Sequence HLA alleles DRM(s)
Pol01 RT(181–189) YQYMDDLYV HLA-A�02:01 Y181C/I/V
M184V/I
Y188C/L/H
Pol02 RT(227–234) FLWMGYEL HLA-A�02:01 F227C
M230I/L
Pol03 RT(232–241) YELHPDKWTV HLA-A�02:01 none
Pol04 RT(158–166) AIFQSSMTK HLA-A�03:01, HLA-A�11:01 none
Pol05 RT(73–82) KLVDFRELNK HLA-A�03:01, HLA-A�11:01 L74V
Pol06 RT(240–249) TVQPIVLPEK HLA-A�11:01 none
Pol07 RT(110–118) DVGDAYFSV HLA-A�68:02 Y115F
Pol08 RT(156–164) SPAIFQSSM HLA-B�07:02, HLA-B�35:01 none
Pol09 RT(18–26) GPKVKQWPL HLA-B�08:01 none
Pol10 RT(163–171) SMTKILEPF HLA-B�15:01 none
Pol11 RT(107–115) TVLDVGDAY HLA-B�35:01 Y115F
Gag01 Gag(362–370) VLAEAMSQV HLA-A�02:01 none
Gag02 Gag(433–440) FLGKIWPS HLA-A�02:01 none
Gag03 Gag(148–156) SPRTLNAWV HLA-B�07:02 none
Nef01 Nef(134–143) RYPLTFGWCY HLA-A�24:02 none
https://doi.org/10.1371/journal.pone.0212347.t002
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results seemed encouraging so we validated the above mentioned list to synthesize the corre-
sponding peptides, which will be used in the following part of the research program. Since
there is an inversed relationship between similarity of HIV to its host and its immunogenicity
[21], we carried out further analysis of peptide sequences and reactive peptides were shown to
have low sequence similarities with host genome sequences.
Five epitopes identified here overlapped positions that have been related to drug resistance
mutations (DRMs), here exclusively to NRTI and NNRTI since they are located in RT: Pol01,
Pol02, Pol05, Pol07 and Pol11. There were few DRMs in these areas of the investigated proviral
DNA and, when observed, they had no consequence on the theoretical affinity of the epitope
for the HLA groove. We then simulated some DRMs in selected epitopes. For example, epitope
RT 181–189 (Pol01) may face some DRMs to 3TC/FTC and to NNRTIs at residues 181 (Y to
C/I/V), 184 (M to V/I) or 188 (Y to C/H/L). The 184V DRM alone does not impair the affinity
of the epitope for the HLA-A�02:01. Cumulated DRMs 181C, 184V plus 188C theoretically
cancel this affinity (MHC IC50 > 2,400 nm). The epitope KLVDFRELNK at RT 73–82 (Pol05)
can host DRM 74 V/I to abacavir and tenofovir (in association with other DRMs), but the
switch of residue 74 L to V or I has no theoretical consequence on the affinity to HLA-A alleles
A�03:01 and A�11:01. The epitopes RT 107–115 (Pol11) and 110–118 (Pol07) may host the
mutation 115F to abacavir but without any negative consequence on presentation by alleles
B�35:01 and A�68:02, respectively.
Discussion
The aim of the present study was to identify conserved CTL epitopes in integrated HIV-1 with
high predicted binding affinity to most common HLA class I alleles to serve as the basis of fur-
ther T cell immunogen design. Integrated DNA was analysed since virus rebound after cART
interruption is believed to originate from such archived DNA.
The study has some limitations and raises some important issues. First, we analyzed global
archived DNA molecules without differentiating noninfectious and replication competent
genomes. It would be pertinent to use and clone CD4+ memory T cells and express the infec-
tious viral particles [17]. However, there has been an ethical limitation in the available blood
volumes. The reading coverage of NGS sequencing was high in the study and since we only
Fig 1. Plot representation of HIV epitope variants per patient according to their MHC IC50 score. For each of our conserved epitopes, one dot represents one
patient’s HIV epitope variant according to i) its percentage of frequency calculated from NGS results and ii) its ability to bind the corresponding HLA groove. The color
displays the MHC IC50 score: green IC50< 50 nM; blue 50< IC50 < 500 nM and orange IC50 > 500 nM. The crosses indicate variants with stop codons.
https://doi.org/10.1371/journal.pone.0212347.g001
A computational analysis of conserved HIV-1 proviral CTL epitopes
PLOS ONE | https://doi.org/10.1371/journal.pone.0212347 February 27, 2019 5 / 11
rarely observed escape variants at the epitopic areas of interest, we hypothesize but cannot
proove that these data would also apply to replication competent infectious genomes inside
the DNA molecules analyzed.
Another issue is the conservation of epitopes. The fact that most of the conserved CTL epi-
topes in RT are located in the thumb or palm of the enzyme implies some potential functional
constraints that limit their variability. The range of variation of the epitopes in Gag, Pol and
Nef might also be limited by other unknown constraints, as it has been pointed out for Nef
[22]. Furthermore, there are not many epitopes in Gag with an MHC IC50<50 nm, yet the
CD8+ T-cell responses to Gag are considered to be crucial for decreasing viremia at the end of
the primary infection phase [23]. In fact, more Gag epitopes were noted in the range 50 nm-
500 nm, but since we had decided to record those exhibiting a theoretical affinity associated
with an MHC IC50 < 50nm, we did not list them here. For instance, the well-known Gag SL9
epitope did not meet our criteria for selection since it was had a theoretical affinity above 50
nm (192.7 nm) for HLA-A�02:01. As a consequence, our conservative approach may have
missed some potential epitope candidates which may limit the breath of responses upon vacci-
nation. It would be certainly interesting to explore the immunogenicity of epitopes with higher
binding affinity, including those up to 500nm threshold which has been suggested to provide a
relevant cut-off for effective CTL epitopes [24].
Furthermore, it remains to be shown that T cell responses to the conserved epitopes identi-
fied here have antiviral activity in vivo. As mentioned above, at least some HIV-infected CD4
+ cells in cART-treated patients are able to translate Gag, Pol and Nef proteins although they
do not contain a fully replication competent provirus [7]. This would suggest that the con-
served epitopes that we have observed in archived proviral genomes could be presented to spe-
cific T cells even in cART suppressed patients [25]. However, the amount of antigen produced
may be limiting to induce or maintain a robust CD8+ T cell response so that the responses
may need to be induced by potent vaccination.
Another issue is the efficacy of CD8+ T-cell stimulation in cART-treated patients. It is now
accepted that “T-cell exhaustion” occurs in chronic untreated HIV infections, which impairs
the response of CD8+ T-cells to antigens and maybe those cited above [25,26]. During cART,
CD8+ T-cells exhibit improved function and may respond to injected CTL peptides.
An additional factor that may hamper the in vivo efficacy of response to the above defined
epitopes is the compartmentalization of host immune responses to HIV. For example, the
GALT is an important anatomic reservoir of the virus and it has been demonstrated that resi-
dent CD8+ T-cells (Trm) are expanded in the tissues and do not circulate, so they cannot be
investigated in the blood for their functional properties [27]. As yet it is not possible to know
what the effect of peripheral vaccination would be on these tissue cells. Moreover, the full iden-
tity of the CTL epitopes archived in the peripheral blood compartment versus the GALT is
unclear. Some published data seem to indicate at least that HIV-1 does not evolve in this com-
partment under efficient cART [28]. At present we are carrying out a comparative study of the
CTL epitopes of archived proviral DNA in these two compartments.
In conclusion, we have screened more than 200 patients’HIV proviral sequences for con-
served CTL epitopes presented by the most common HLA class I alleles of the studied popula-
tion. Some of these epitopes have been described in the listing of optimal CTL epitopes of the
Los Alamos Immunology database; others are newly described epitopes resulting from our in-
silico analysis. The reasons for the conservation of these epitopes may be due to functional
constraints. Alternatively, however, they may be conserved since they are not targeted or
“underutilized” by the immune system during the natural infection [29] and are therefore not
under selective pressure. They may represent valuable epitopes candidates for inclusion in a
multi-epitopic HLA-fitted vaccine (HFVAC) that could be refined with the addition of further
A computational analysis of conserved HIV-1 proviral CTL epitopes
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conserved epitopes presented by dominant HLA alleles of populations from other parts of the
world as has been proposed for the Chinese population [30]. The next step will be (i) to per-
form ELISPOT with PBMC from Provir/Latitude45 volunteers using HFVAC as an antigen
source, and (ii) to assess its toxicity and measure the CTL response in an animal model.
Materials and methods
The study was authorized by the “Comité de protection des personnes du Sud-Ouest et Outre-
mer” (DC 2012/48). Patients provided informed consent for participation and the written
form of consent; samples were anonymized.
Patients
Samples from 202 patients were obtained from sites in Europe, North America and South
America. Their characteristics are detailed in Table 3. The first 11 patients recruited in France
and the Canadian patients have already been described [15,16]. The patients recruited in Balti-
more have been described elsewhere [31].
Quantitation of proviral DNA and biological follow-up of patients
Extraction of total DNA and quantitation of proviral DNA were carried out as in our previous
studies [15,16]. CD4+ T lymphocytes were counted by flow cytometry and HIV-1 viral load
was measured by commercially available molecular techniques.
HLA typing for HLA-A and-B locus
The method used for the molecular characterization of HLA alleles A and B in the Bordeaux
and Montreal cohorts has been described previously [15,16]. For the patients from Lima, high-
resolution HLA typing was performed by sequence-based typing (SBT) at the University of
Oklahoma Health Science Center, a CLIA/ASHI-accredited HLA typing laboratory.
In Brazil, HLA class I typing was carried out by Illumina NGS sequencing. Briefly, separate
amplifications of the HLA-A, B and C loci comprising the promoter region and exons 1–7
were performed; the fragments obtained have 5.4, 4.6 and 4.8 kB, respectively. They were
subsequently quantified and pooled per sample at a final concentration of 4 nM for the
Table 3. Patients’ main characteristics and general technical strategy of study. Number of included patients, methods of HIV sequencing and HLA typing are
described for each participating center. MHC IC50 was predicted with TutuGenetics tool.
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construction of libraries using the Nextera XT DNA Sample Preparation kit (Illumina Inc.,
San Diego, USA) according to the manufacturer1s protocol. Libraries were quantified by fluo-
rescence using the Qubit dsDNA HS Assay Kit (Life Technologies, Carlsbad, USA) and diluted
to 4 nM according to the mean size and quantification of each library. Products were
sequenced in an Illumina MiSeq platform using 1% denatured PhiX DNA as a sequencing con-
trol. The HLA alleles were typed, commonly at the six-digit resolution (some with eight-digit),
using the commercial software HLA-Twin (Omixon Inc., Budapest, Hungary).
Sanger sequencing of HIV proviral DNA
Proviral DNA Gag and Pol sequencing was carried out followed by Sanger sequencing, as
described in previous Provir studies [15,16]. Near full-length genome sequences were obtained
by Eyzaguirre et al [31]. Nef sequencing was performed after two rounds of PCR using the
following primers: Nef 1–5 (5’-3’: GCCACAGCCATAGCAGTAGCTGAGGGG) and
Nef 1–3 (5’-3’: CCAGTACAGGCAAAAAGCAGCTGCTTATA) for outer PCR
and Nef 2–5 (5’-3’: CCTAGAAGAATAAGACAGGGCTTGGAAAG) and Nef 2–3
(5’-3’: CGCCTCCCTGGAAAGTCCCCAGCGG) for inner PCR.
NGS sequencing of HIV proviral DNA
The sequencing of samples from Bordeaux and Montreal using 454 Roche technology has
already been described [15,16]. For PGM Ion Torrent sequencing, amplicons were purified
prior to enzymatic shearing, adapter and barcode ligation and size selection according to The
Ion Xpress Plus library preparation manual. Template enrichment was performed on the Ion
OneTouch ES Instrument the following day. Prior to PGM sequencing, quality control of the
template was ensured by a Tapestation measurement. Sequencing was performed on the Ion
PGM System with the Ion PGM Sequencing 400 Kit using an Ion 316 chip. For the patients in
Brazil, the MiSeq (Illumina) sequencer was used to produce NGS data of near full-length HIV
genome [32,33]. Raw data (SFF or FASTQ files) were submitted to the Smartgene pipeline as
previously described [34] to generate a BAM file for each patient and each studied gene for
subsequent analysis.
Prediction of affinity between epitopes and HLA alleles
Using our TutuGenetics software [35], we were able to estimate the theoretical affinity between
the putative epitopes and the HLA class I molecules of each patient. The TutuGenetics algo-
rithm moves a sliding window of 8 to 10 amino acids across the test sequence and calculates
the MHC IC50 value according to each HLA allele of each patient to identify theoretically new
HLA-epitope pairs. In order to identify potential epitopes with high binding affinity and con-
served sequence across the available DNA sequence dataset, a conservative cut-off was applied
so that only those epitopes with a theoretical MHC IC50 < 50nm binding affinity and observed
in>80% of all sequences analyzed were included.
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